Hologic, Inc. $HOLX Shares Acquired by Inspire Investing LLC

Inspire Investing LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 41.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,075 shares of the medical equipment provider’s stock after purchasing an additional 1,488 shares during the quarter. Inspire Investing LLC’s holdings in Hologic were worth $313,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HOLX. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the first quarter valued at about $34,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Hologic in the 1st quarter valued at approximately $42,000. Allworth Financial LP raised its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 216 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 722 shares during the period. Finally, West Financial Advisors LLC purchased a new stake in shares of Hologic in the first quarter valued at approximately $50,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Up 7.7%

Shares of HOLX stock opened at $68.20 on Thursday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a market capitalization of $15.17 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 2.30 and a beta of 0.57. The firm has a 50-day moving average price of $66.43 and a 200 day moving average price of $62.69. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business posted $1.06 earnings per share. The company’s revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HOLX shares. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a report on Tuesday, July 8th. UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Morgan Stanley raised their price objective on Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.